文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

镰状细胞病:HLA全合同胞造血干细胞移植结果的国际调查

Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.
PubMed 文献 · Blood · 2016-12-13

该研究纳入1986年至2013年间向欧洲血液与骨髓移植学会、Eurocord及国际血液与骨髓移植研究中心报告的1000例HLA全合同胞移植受者,中位年龄9岁,中位随访超过5年,5年无事件生存率和总生存率分别为91.4%(95%CI 89.6%-93.3%)和92.9%(95%CI 91.1%-94.6%),结论认为HLA全合同胞移植对镰状细胞病儿童和成人具有良好结局。

要点

  • 1000例HLA全合同胞移植受者中,5年无事件生存率为91.4%(95%CI 89.6%-93.3%)。
  • 5年总生存率为92.9%(95%CI 91.1%-94.6%),70例(7%)死亡,最常见死因为感染。
  • 移植时年龄增加与无事件生存率降低相关(HR 1.09;P < .001),2006年后移植的无事件生存率更高(HR 0.95;P = .013)。

核心结论

  • 跨越三十年的队列移植结局良好,证实了HLA全合同胞移植对镰状细胞病儿童和成人的作用。

研究设计与样本

  • 研究纳入1986年至2013年间向欧洲血液与骨髓移植学会、Eurocord及国际血液与骨髓移植研究中心报告的1000例HLA全合同胞移植受者。
  • 主要终点为无事件生存,定义为存活且无移植物失败;采用Cox回归模型分析危险因素。

主要发现

  • 移植时中位年龄为9岁,中位随访时间超过5年。
  • 大多数患者接受清髓性预处理方案(n = 873;87%),其余接受减低强度预处理方案(n = 125;13%)。
  • 骨髓是主要干细胞来源(n = 839;84%),外周血和脐带血祖细胞分别用于73例(7%)和88例(9%)患者。
  • 5年无事件生存率和总生存率分别为91.4%(95%CI 89.6%-93.3%)和92.9%(95%CI 91.1%-94.6%)。
  • 无事件生存率随移植时年龄增加而降低(HR 1.09;P < .001),2006年后进行的移植无事件生存率更高(HR 0.95;P = .013)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advances in supportive therapy to prevent complications of sickle cell disease (SCD), access to care is not universal. Hematopoietic cell transplantation is, to date, the only curative therapy for SCD, but its application is limited by availability of a suitable HLA-matched donor and lack of awareness of the benefits of transplant. Included in this study are 1000 recipients of HLA-identical sibling transplants performed between 1986 and 2013 and reported to the European Society for Blood and Marrow Transplantation, Eurocord, and the Center for International Blood and Marrow Transplant Research. The primary endpoint was event-free survival, defined as being alive without graft failure; risk factors were studied using a Cox regression models. The median age at transplantation was 9 years, and the median follow-up was longer than 5 years. Most patients received a myeloablative conditioning regimen (n = 873; 87%); the remainder received reduced-intensity conditioning regimens (n = 125; 13%). Bone marrow was the predominant stem cell source (n = 839; 84%); peripheral blood and cord blood progenitors were used in 73 (7%) and 88 (9%) patients, respectively. The 5-year event-free survival and overall survival were 91.4% (95% confidence interval, 89.6%-93.3%) and 92.9% (95% confidence interval, 91.1%-94.6%), respectively. Event-free survival was lower with increasing age at transplantation (hazard ratio [HR], 1.09; P < .001) and higher for transplantations performed after 2006 (HR, 0.95; P = .013). Twenty-three patients experienced graft failure, and 70 patients (7%) died, with the most common cause of death being infection. The excellent outcome of a cohort transplanted over the course of 3 decades confirms the role of HLA-identical sibling transplantation for children and adults with SCD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2016. PMID: 27965196. doi:10.1182/blood-2016-10-745711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。